View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
November 10, 2009

Novartis Three-in-One Blood Pressure Drug Approved in EU

Novartis has been granted authorisation from the European Commission to market Exforge HCT, its new three-in-one once-daily treatment for high blood pressure. Exforge HCT is a combination of three commonly used blood pressure medications: the angiotensin receptor blocker valsartan (Diova

By cms admin

Novartis has been granted authorisation from the European Commission to market Exforge HCT, its new three-in-one once-daily treatment for high blood pressure.

Exforge HCT is a combination of three commonly used blood pressure medications: the angiotensin receptor blocker valsartan (Diovan), the calcium channel blocker amlodipine and the diuretic hydrochlorothiazide (HCT).

Novartis Pharmaceuticals Division CEO Joe Jimenez said that Novartis is committed to helping patients improve their treatment compliance.

“Simplified treatment regimens and reduced pill burdens have been shown to help achieve this,” Jimenez said.

High blood pressure is one of the leading causes of cardiovascular disease and although treatable it is often exacerbated by patient-related treatment failure. Patients therefore may find treatment more convenient with one single pill rather than multiple separate pills.

EU approval was supported by the results of Study 230211, a multinational, randomised, double-blind, parallel-group, Phase III study conducted in 15 countries, with 2,271 patients randomised to double-blind treatment.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology